Age of 58 y, male, visual acuity was decreased to 0.4 at visit 04/2012. The case is documented by fundus photography, fluorescein angiography, and OCT. The presented case demonstrates the visual and anatomical effect of an intravitreal injection of bevacizumab (Avastin, Genentech) on macular edema due to non-ischemic branch retinal vein occlusion. Fundus photography (1), fluorescein angiography (2), and OCT (3) documented capillary dilatations, a cystoid maculopathy and small intraretinal hemorrhages. Intravitreal bevacizumab (10 mg) was given in 05/2012. Visual acuity (VA) improved from 0.4 at the visit 04/2012 to 0.8 at the visit 06/2012. Central macular thickness (CMT) measured 558 microns at visit 04/2012 and 294 microns at visit 06/2012. VA gain was positively correlated with CMT reduction. In literature (1) in patients with BRVO the non- ischemic type of BRVO was found in about 45% with a mean visual acuity 0.4 (20/50). Only in about 15% preretinal neovascularisation was visible. Cystoid macular edema was present in about 45%, a combination of cystoid and ischemic maculopathy in about 20%. Literature: 1. Klin Monbl Augenheilkd. 1992 Oct;201(4):234-9. Clinical and fluorescein angiography findings in patients with retinal vein occlusion. A unicenter study of 211 patients.Lang GE, Freissler K.